mental health

Depression, schizophrenia, ADHD and other psychiatric conditions: drugs, tests and behavioral health services.

Theme · 4 companies · 1 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ABBV AbbVie

    Sells it“Vraylar is indicated for acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar disorder in adults, acute treatment of depressive episodes associated with bipolar I disorder in adults and as an adjunctive treatment in major depressive disorder.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • ELV Elevance Health

    Sells it“Carelon Services benefited from expansion in risk-based specialty and behavioral health and stronger specialty/home-based care performance, partly offset by the unaffiliated contract change and less favorable behavioral-health contract results.”

    Latest 8-KGuidance reaffirmed ·

    FY2026 outlook reaffirmed for investor meetings: EPS of at least $22.00 diluted and $29.00 adjusted.

  • MYGN Myriad Genetics

    Sells it 17%, $144.1M a year“Leveraging pharmacogenomics to help clinicians understand how genetics may impact patient metabolism and response to antidepressants and other mental health medications.”

    Latest 8-KExecutive pay ·

    One-time retention options for the CFO, COO and chief scientific officer support leadership continuity as Myriad works to improve efficiency.

  • VRHI Veri MedTech Holdings, Inc.

    In development“ADHD and Mental Health Treatment”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueControlled company ·

    Connects patients with physicians for medical-cannabis certifications; FY2025 revenue fell 34.9% Y/Y as state restrictions hit consultations

Feedback